Abstract
Immune thrombocytopenia, known as immune thrombocytopenic purpura (ITP), has emerged as a major complication of COVID-19. A comprehensive approach is required to diagnose ITP associated with COVID-19. In this study, 7 patients who were diagnosed with ITP in the first 60 days after COVID-19 PCR positivity were presented. The median platelet count of the patients at diagnosis is 16x109/L. There was no severe life-threatening bleeding. The median day from the onset of COVID-19 symptoms to the diagnosis of ITP was 21 days. Various mechanisms such as bone marrow suppression, platelet consumption due to microvascular thrombus, or autoimmune destruction of platelets may be the cause of COVID-19-associated thrombocytopenia. Response to IVIG treatment was achieved, but relapse developed in a median of 13 days after IVIG. Corticosteroids can be used in patients with relapse. Care should be taken in terms of the development of thrombocytopenia in patients after COVID-19. Patients with newly diagnosed ITP should be tested for COVID-19.